A mechanistic proof-of-concept clinical trial with JX-594, a targeted multi-mechanistic oncolytic poxvirus, in patients with metastatic melanoma

Molecular Therapy

Volumn 19, Issue 10, 2011, Pages 1913-1922

  Hwang, Tae Ho ^a   Moon, Anne ^b   Burke, James ^b,c   Ribas, Antoni ^d   Stephenson, Joe ^e   Breitbach, Caroline J ^b   Daneshmand, Manijeh ^f   De Silva, Naomi ^f   Parato, Kelley ^f   Diallo, Jean Simon ^f   Lee, Yeon Sook ^a   Liu, Ta Chiang ^b   Bell, John C ^f   Kirn, David H ^b  

^a Pusan National University   (South Korea)

^b Jennerex Inc   (United States)

^c BILLINGS CLINIC   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e Department of US Oncology ^*  (United States)

^f OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BETA GALACTOSIDASE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; JX 594; ONCOLYTIC POXVIRUS; ONCOLYTIC VIRUS; UNCLASSIFIED DRUG;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BLOOD CLOTTING TEST; BLOOD SAMPLING; CALCIUM BLOOD LEVEL; CANCER PAIN; CANCER STAGING; CELL DEATH; CELL POPULATION; CHILL; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CYTOPENIA; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG FATALITY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; DYSGEUSIA; DYSPEPSIA; DYSPNEA; EDEMA; ERYTHEMA; ESOPHAGITIS; FACE PAIN; FATIGUE; FEMALE; FLU LIKE SYNDROME; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERGLYCEMIA; HYPOGLYCEMIA; IMMUNOSTIMULATION; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE PRURITUS; INJECTION SITE RASH; LEUKOCYTE COUNT; LOW DRUG DOSE; LYMPHOCYTIC INFILTRATION; MALE; MAXIMUM TOLERATED DOSE; MELANOMA; METASTASIS POTENTIAL; MULTIPLE CYCLE TREATMENT; MUSCULOSKELETAL DISEASE; MYALGIA; NAUSEA; NEUTROPHIL COUNT; PAIN; PALLIATIVE THERAPY; PARTIAL THROMBOPLASTIN TIME; PHARMACODYNAMICS; POTASSIUM BLOOD LEVEL; PROTEIN BLOOD LEVEL; PROTHROMBIN TIME; RADIOGRAPHY; SIDE EFFECT; SODIUM BLOOD LEVEL; SPINAL CORD COMPRESSION; SURVIVAL TIME; TRANSGENE; TUMOR BIOPSY; TUMOR CELL DESTRUCTION; TUMOR NECROSIS; URTICARIA; VIRUS EXPRESSION; VIRUS REPLICATION; VOMITING;

POXVIRIDAE;

EID: 80053564947     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2011.132     Document Type: Article

References (29)

1. Parato, KA, Senger, D, Forsyth, PA and Bell, JC (2005). Recent progress in the battle between oncolytic viruses and tumours. Nat Rev Cancer 5: 965-976. (Pubitemid 41766784)
2. Cattaneo, R, Miest, T, Shashkova, EV and Barry, MA (2008). Reprogrammed viruses as cancer therapeutics: targeted, armed and shielded. Nat Rev Microbiol 6: 529-540. (Pubitemid 351850977)
3. Kirn, DH and Thorne, SH (2009). Targeted and armed oncolytic poxviruses: a novel multi-mechanistic therapeutic class for cancer. Nat Rev Cancer 9: 64-71.
4. Liu, TC, Galanis, E and Kirn, D (2007). Clinical trial results with oncolytic virotherapy: a century of promise, a decade of progress. Nat Clin Pract Oncol 4: 101-117. (Pubitemid 46189539)
5. Msaouel, P, Dispenzieri, A and Galanis, E (2009). Clinical testing of engineered oncolytic measles virus strains in the treatment of cancer: an overview. Curr Opin Mol Ther 11: 43-53.
6. Senzer, NN, Kaufman, HL, Amatruda, T, Nemunaitis, M, Reid, T, Daniels, G et al. (2009). Phase II clinical trial of a granulocyte-macrophage colony-stimulating factorencoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma. J Clin Oncol 27: 5763-5771.
7. De Clercq, E (2002). Cidofovir in the therapy and short-term prophylaxis of poxvirus infections. Trends Pharmacol Sci 23: 456-458. (Pubitemid 35279606)
8. Wittek, R (2006). Vaccinia immune globulin: current policies, preparedness, and product safety and efficacy. Int J Infect Dis 10: 193-201.
9. Mastrangelo, MJ, Maguire, HC Jr, Eisenlohr, LC, Laughlin, CE, Monken, CE, McCue, PA et al. (1999). Intratumoral recombinant GM-CSF-encoding virus as gene therapy in patients with cutaneous melanoma. Cancer Gene Ther 6: 409-422. (Pubitemid 129667814)
10. Kim, JH, Oh, JY, Park, BH, Lee, DE, Kim, JS, Park, HE et al. (2006). Systemic armed oncolytic and immunologic therapy for cancer with JX-594, a targeted poxvirus expressing GM-CSF. Mol Ther 14: 361-370. (Pubitemid 44184970)
11. Merrick, AE, Ilett, EJ and Melcher, AA (2009). JX-594, a targeted oncolytic poxvirus for the treatment of cancer. Curr Opin Investig Drugs 10: 1372-1382.
12. Gnant, MF, Noll, LA, Irvine, KR, Puhlmann, M, Terrill, RE, Alexander, HR Jr et al. (1999). Tumor-specific gene delivery using recombinant vaccinia virus in a rabbit model of liver metastases. J Natl Cancer Inst 91: 1744-1750. (Pubitemid 29518770)
13. Buller, RM, Smith, GL, Cremer, K, Notkins, AL and Moss, B (1985). Decreased virulence of recombinant vaccinia virus expression vectors is associated with a thymidine kinase-negative phenotype. Nature 317: 813-815. (Pubitemid 16195408)
14. Stojdl, DF, Lichty, B, Knowles, S, Marius, R, Atkins, H, Sonenberg, N et al. (2000). Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus. Nat Med 6: 821-825. (Pubitemid 30469434)
15. Hengstschläger, M, Pfeilstöcker, M and Wawra, E (1998). Thymidine kinase expression. A marker for malignant cells. Adv Exp Med Biol 431: 455-460.
16. Thorne, SH, Hwang, TH, O'Gorman, WE, Bartlett, DL, Sei, S, Kanji, F et al. (2007). Rational strain selection and engineering creates a broad-spectrum, systemically effective oncolytic poxvirus, JX-963. J Clin Invest 117: 3350-3358. (Pubitemid 350096991)
17. Dranoff, G, Jaffee, E, Lazenby, A, Golumbek, P, Levitsky, H, Brose, K et al. (1993). Vaccination with irradiated tumor cells engineered to secrete murine granulocytemacrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA 90: 3539-3543. (Pubitemid 23111402)
18. Park, BH, Hwang, T, Liu, TC, Sze, DY, Kim, JS, Kwon, HC et al. (2008). Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial. Lancet Oncol 9: 533-542.
19. Hammond, JM, Oke, PG and Coupar, BE (1997). A synthetic vaccinia virus promoter with enhanced early and late activity. J Virol Methods 66: 135-138. (Pubitemid 27293935)
20. Peng, KW, TenEyck, CJ, Galanis, E, Kalli, KR, Hartmann, LC and Russell, SJ (2002). Intraperitoneal therapy of ovarian cancer using an engineered measles virus. Cancer Res 62: 4656-4662.
21. McCart, JA, Mehta, N, Scollard, D, Reilly, RM, Carrasquillo, JA, Tang, N et al. (2004). Oncolytic vaccinia virus expressing the human somatostatin receptor SSTR2: molecular imaging after systemic delivery using 111In-pentetreotide. Mol Ther 10: 553-561. (Pubitemid 39186116)
22. Msaouel, P, Iankov, ID, Allen, C, Aderca, I, Federspiel, MJ, Tindall, DJ et al. (2009). Noninvasive imaging and radiovirotherapy of prostate cancer using an oncolytic measles virus expressing the sodium iodide symporter. Mol Ther 17: 2041-2048.
23. Smith, GL, Symons, JA, Khanna, A, Vanderplasschen, A and Alcamí, A (1997). Vaccinia virus immune evasion. Immunol Rev 159: 137-154. (Pubitemid 27499865)
24. Zou, W (2005). Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer 5: 263-274. (Pubitemid 40488632)
25. Hovgaard, D, Mortensen, BT, Schifter, S and Nissen, NI (1992). Clinical pharmacokinetic studies of a human haemopoietic growth factor, GM-CSF. Eur J Clin Invest 22: 45-49.
26. Sze, DY, Freeman, SM, Slonim, SM, Samuels, SL, Andrews, JC, Hicks, M et al. (2003). Dr. Gary J. Becker Young Investigator Award: intraarterial adenovirus for metastatic gastrointestinal cancer: activity, radiographic response, and survival. J Vasc Interv Radiol 14: 279-290. (Pubitemid 36314756)
27. Wolchok, JD, Hoos, A, O'Day, S, Weber, JS, Hamid, O, Lebbé, C et al. (2009). Guidelines for the evaluation of immune therapy activity in solid tumors: immunerelated response criteria. Clin Cancer Res 15: 7412-7420.
28. Kulesh, DA, Baker, RO, Loveless, BM, Norwood, D, Zwiers, SH, Mucker, E et al. (2004). Smallpox and pan-orthopox virus detection by real-time 3'-minor groove binder TaqMan assays on the roche LightCycler and the Cepheid smart Cycler platforms. J Clin Microbiol 42: 601-609. (Pubitemid 38222635)
29. Therasse, P, Arbuck, SG, Eisenhauer, EA, Wanders, J, Kaplan, RS, Rubinstein, L et al. (2000). New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92: 205-216. (Pubitemid 30099779)